Gland Pharma schedules analyst meeting on June 25, 2026

0 min read     Updated on 23 Jun 2026, 12:13 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Gland Pharma has scheduled a one-on-one analyst and institutional investor meeting with Ambit PMS for June 25, 2026, arranged by B&K / 360One. The disclosure was made under SEBI regulations, and the schedule remains subject to change due to exigencies.

powered bylight_fuzz_icon
43690574

*this image is generated using AI for illustrative purposes only.

Gland Pharma has scheduled an analyst and institutional investor meeting for June 25, 2026. The meeting will be a one-on-one session with Ambit PMS, arranged by B&K / 360One. This interaction is part of the company's ongoing engagement with the investment community.

The disclosure was made pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule of the meeting is subject to change, which may occur due to exigencies on the part of the investor, analyst, or the company.

Meeting Schedule

Date Investor/Analyst/Fund Name Type of Meeting
June 25, 2026 Ambit PMS arranged by B&K / 360One One-on-One Meetings

The intimation was signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer of Gland Pharma Limited.

Historical Stock Returns for Gland Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+5.10%+3.85%-1.53%+36.20%+31.75%-27.80%

What key topics or strategic updates is Gland Pharma likely to discuss during this meeting?

How might the outcomes of this engagement influence investor sentiment toward Gland Pharma?

Could this meeting signal potential upcoming corporate actions or partnerships for the company?

Gland Pharma seeks nod for director appointments and pay

2 min read     Updated on 20 Jun 2026, 10:18 AM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Gland Pharma Limited has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Udo Johannes Vetter and the appointment of Mr. William Robert Keller as Independent Directors. The resolutions also include a proposal to pay a commission on profits, capped at INR 5,500,000 per annum, to these directors and to revise the remuneration for Mr. Essaji Goolam Vahanvati. The remote e-voting period is open from June 19, 2026, to July 18, 2026.

powered bylight_fuzz_icon
43069961

*this image is generated using AI for illustrative purposes only.

Gland Pharma Limited has initiated a postal ballot process seeking shareholder approval for the re-appointment of Mr. Udo Johannes Vetter and the appointment of Mr. William Robert Keller as Independent Directors. The resolutions also include a proposal to pay a commission on profits, capped at INR 5,500,000 per annum, to these directors and to revise the remuneration for Mr. Essaji Goolam Vahanvati. The remote e-voting period is open from June 19, 2026, to July 18, 2026.

The Board meeting held on June 15, 2026, approved the re-appointment of Mr. Udo Johannes Vetter for a second term of five consecutive years effective from July 21, 2026, to July 20, 2031. Mr. Vetter, aged 72, currently serves as Chairman of the ITM Group, Germany, and brings over 40 years of experience in the pharmaceutical sector. The Board also approved the appointment of Mr. William Robert Keller, aged 78, as an Independent Director for a term of five years from June 15, 2026, to June 14, 2031. Mr. Keller is currently an Independent Director of Wuxi Biologics and Hua Medicine.

Shareholders are being asked to approve a commission of 0.15% on the audited net profits of the Company, subject to a maximum of INR 5,500,000 per annum, for Mr. Udo Johannes Vetter and Mr. William Robert Keller. Additionally, the notice seeks approval to revise the commission on profits for Mr. Essaji Goolam Vahanvati from 0.1% to 0.15%, with the cap increasing from INR 2.5 Million to INR 5.5 Million per annum for his remaining term. These commissions are in addition to sitting fees for attending Board and Committee meetings.

The postal ballot notice is being sent electronically to members whose names appear on the Register of Members as on the cut-off date of June 12, 2026. The remote e-voting facility, provided by MUFG Intime India Private Limited, commences on June 19, 2026, at 09:00 AM IST and concludes on July 18, 2026, at 05:00 PM IST. The results of the postal ballot will be announced on or before July 20, 2026.

Resolutions Summary

Resolution Details
Re-appointment Mr. Udo Johannes Vetter as Independent Director (July 21, 2026 to July 20, 2031)
Appointment Mr. William Robert Keller as Independent Director (June 15, 2026 to June 14, 2031)
Remuneration Commission of 0.15% on net profits, capped at INR 5,500,000 p.a. for Mr. Vetter and Mr. Keller
Remuneration Revision Commission for Mr. Essaji Goolam Vahanvati revised to 0.15%, capped at INR 5,500,000 p.a.
E-voting Period June 19, 2026 (09:00 AM IST) to July 18, 2026 (05:00 PM IST)

Ms. D. Soumya, Practicing Company Secretary, has been appointed as the Scrutinizer for the postal ballot process. The resolutions require a special resolution for the appointments and an ordinary resolution for the remuneration proposals. The Board has recommended all resolutions for approval.

Historical Stock Returns for Gland Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+5.10%+3.85%-1.53%+36.20%+31.75%-27.80%

How will the extensive global experience of the newly appointed directors influence Gland Pharma's strategic expansion into regulated markets like the US and Europe?

What impact will the increased remuneration structure have on shareholder sentiment regarding corporate governance and cost management?

Does the appointment of directors aged 72 and 78 signal a potential gap in the company's succession planning for younger leadership?

More News on Gland Pharma

1 Year Returns:+31.75%